Drug Trial Radar · NCT07349212
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 18, 2026
Primary completion
Mar 1, 2027
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- Ukko IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Conditions
- Peanut-Induced Anaphylaxis
- Peanut Allergy
Interventions
UKK-0018Biological
UKK0018 is an immunotherapeutic treatment of peanut allergies
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of solicited local and systemic adverse reactionsTime frame: 7 days after each injection
- To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of unsolicited adverse eventsTime frame: 28 days after each injection
- To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of medically-attended adverse events (MAAEsTime frame: 30 weeks after first injection
- To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of adverse events of special interest (AESI)Time frame: 30 weeks after first injection
- To assess the safety and tolerability of repeated dosing of UKK-0018 administered IM of serious adverse events (SAE)Time frame: 30 weeks after first injection
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
St Vincents Hospital
Darlinghurst, New South Wales, Australia · Recruiting
Flinders Medical Center
Bedford Park, South Australia, Australia · Not yet recruiting
The Royal Melbourne Hospital
Fitzroy, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Perth, Western Australia, Australia · Recruiting
Pacific Clinical Research Network - Auckland
Takapuna, Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.